<DOC>
	<DOCNO>NCT00226369</DOCNO>
	<brief_summary>We conduct multicenter , randomize , placebo-controlled trial Cylexin , inhibitor attachment white blood cell endothelium . Our study population neonates infant undergo hypothermic cardiopulmonary bypass surgical repair palliation congenital heart defect .</brief_summary>
	<brief_title>Cylexin Reduction Reperfusion Injury Infant Heart Surgery</brief_title>
	<detailed_description>Ischemia/reperfusion ( I/R ) injury important adverse effect cardiopulmonary bypass ( CPB ) infant undergo cardiac surgery . We perform multicenter , randomize , placebo-controlled , double-blinded trial leukocyte-endothelial cell adhesion inhibitor Cylexin young infant determine reduces I/R injury follow hypothermic CPB . Entry criterion include age surgery 1-45 day , birth weight &gt; 2.3 kg , plan repair palliation congenital heart defect CPB . We exclude patient specified antecedent event condition , include lung kidney disease , seizures , necrotizing enterocolitis , infection , serious noncardiac morbidity . Randomization stratify study center cardiac diagnosis . Cylexin administer continuously sternotomy 24 hour post CPB . Centers follow usual operative postoperative care practice . From December 1997-March 1999 , enrol 230 infant , 155 2-ventricle repair ( Group 1 : D-TGA=90 , VSD=16 , TOF/truncus=22 , TAPVR=9 , VSD aortic arch obstruction=18 ) 75 stage 1 palliation ( Group 2 : single ventricle aortic arch obstruction ) . Of enrolled , 117 assign Cylexin ( Group 1=80 , Group 2=47 ) 113 placebo ( Group 1=75 , Group 2=38 ) . Pre- intraoperative variable comparable treatment group . Early ( 30 day ) mortality Cylexin versus placebo patient Group 1 0 % versus 3.8 % ( p=0.25 ) Group 2 10.8 % versus 28.9 % ( p=0.08 ) . In risk group , treatment Cylexin significantly improve early postoperative outcome decrease occurrence adverse event . Cylexin significantly improve early mortality postoperative recovery Group 1 patient . Despite small sample size , early mortality Group 2 Cylexin-treated patient tend low , suggest need future trial agent could reduce I/R injury high-risk infant .</detailed_description>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<criteria>1 ) schedule cardiac surgery hypothermic CPB repair either Dtransposition great artery ( DTGA ) intact ventricular septum ( IVS ) ventricular septal defect ( VSD ) , VSD without aortic arch obstruction ( AAO ) , tetralogy Fallot ( TOF ) without pulmonary atresia ( PA ) , truncus arteriosus , total anomalous pulmonary venous return ( TAPVR ) , double outlet right ventricle ( DORV ) , palliate hypoplastic leave heart syndrome ( HLHS ) form single ventricle ( SV ) AAO use stage I ( Norwood ) operation , 2 ) age 145 day surgery , 3 ) birth weight &gt; 2.3 kg , 4 ) cranial ultrasound &lt; 1 week prior enrollment show grade II hemorrhage high risk patient Exclusion criterion include follow : 1 ) need urgent cardiac surgery , 2 ) cardiac arrest ≤ 1 week surgery , 3 ) prior procedure hypothermic CPB , 4 ) acute chronic infection , 5 ) major noncardiac congenital anomaly chromosomal abnormality , 6 ) preoperative arterial pH ≤ 7.0 , 7 ) significant noncardiac organ dysfunction renal failure , respiratory failure , seizure , necrotizing enterocolitis , 8 ) use another investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Days</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Cardiopulmonary bypass</keyword>
	<keyword>Congenital heart disease</keyword>
	<keyword>Reperfusion injury</keyword>
</DOC>